Q-omics provides the consensus-scored MTRNR2L3 profile across patient tissues and cancer cell-line models. MTRNR2L3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MTRNR2L3 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MTRNR2L3 RNA expression shows 15,396 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KICH, and ACC as cancer lineages where MTRNR2L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRNR2L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRNR2L3 survival associations across molecular data types. MTRNR2L3 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRNR2L3 RNA expression–survival associations across cancer types. High MTRNR2L3 expression shows unfavorable associations in UCS and BRCA, but favorable associations in ACC, BLCA, PAAD and LAML. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for MTRNR2L3 RNA expression.
This table summarizes MTRNR2L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTRNR2L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRNR2L3 shows lower tumor expression in HNSC, BRCA, LIHC and KIRC and higher tumor expression in KICH and BRCA. The KICH box plot shows higher MTRNR2L3 RNA expression in tumor versus normal tissue (log2 FC = +0.245, t-test p = .002).
This table shows molecular features associated with MTRNR2L3 in patient tissues and cancer cell lines. In patient samples, MTRNR2L3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRNR2L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
